Subclinical Left Ventricular Dysfunction During Chemotherapy

Subclinical left ventricular dysfunction is the most common cardiac complication after chemotherapy administration. Detection and early treatment are major issues for better cardiac outcomes in this cancer population. The most common definition of cardiotoxicity is a 10-percentage point decrease of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Martin Nicol, Mathilde Baudet, Alain Cohen-Solal
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2019
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/d54911864c4841cab1ed25766781d4e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d54911864c4841cab1ed25766781d4e9
record_format	dspace
spelling	oai:doaj.org-article:d54911864c4841cab1ed25766781d4e92021-12-04T16:00:50ZSubclinical Left Ventricular Dysfunction During Chemotherapy10.15420/cfr.2018.25.12057-75592057-7540https://doaj.org/article/d54911864c4841cab1ed25766781d4e92019-01-01T00:00:00Zhttps://www.cfrjournal.com/articles/subclinical-LV-dysfunction-chemotherapyhttps://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Subclinical left ventricular dysfunction is the most common cardiac complication after chemotherapy administration. Detection and early treatment are major issues for better cardiac outcomes in this cancer population. The most common definition of cardiotoxicity is a 10-percentage point decrease of left ventricular ejection fraction (LVEF) to a value <53%. The myocardial injury induced by chemotherapies is probably a continuum starting with cardiac biomarkers increase before the occurence of a structural myocardial deformation leading to a LVEF decline. An individualised risk profile (depending on age, cardiovascular risk factors, type of chemotherapy, baseline troponin, baseline global longitudinal strain and baseline LVEF) has to be determined before starting chemotherapy to consider cardioprotective treatment. To date, there is no proof of a systematic cardioprotective treatment (angiotensin-converting enzyme inhibitor and/or betablocker) in all cancer patients. However, early cardioprotective treatment in case of subclinical left ventricular dysfunction seems to be promising in the prevention of cardiac events.Martin NicolMathilde BaudetAlain Cohen-SolalRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 5, Iss 1, Pp 31-36 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Martin Nicol Mathilde Baudet Alain Cohen-Solal Subclinical Left Ventricular Dysfunction During Chemotherapy
description	Subclinical left ventricular dysfunction is the most common cardiac complication after chemotherapy administration. Detection and early treatment are major issues for better cardiac outcomes in this cancer population. The most common definition of cardiotoxicity is a 10-percentage point decrease of left ventricular ejection fraction (LVEF) to a value <53%. The myocardial injury induced by chemotherapies is probably a continuum starting with cardiac biomarkers increase before the occurence of a structural myocardial deformation leading to a LVEF decline. An individualised risk profile (depending on age, cardiovascular risk factors, type of chemotherapy, baseline troponin, baseline global longitudinal strain and baseline LVEF) has to be determined before starting chemotherapy to consider cardioprotective treatment. To date, there is no proof of a systematic cardioprotective treatment (angiotensin-converting enzyme inhibitor and/or betablocker) in all cancer patients. However, early cardioprotective treatment in case of subclinical left ventricular dysfunction seems to be promising in the prevention of cardiac events.
format	article
author	Martin Nicol Mathilde Baudet Alain Cohen-Solal
author_facet	Martin Nicol Mathilde Baudet Alain Cohen-Solal
author_sort	Martin Nicol
title	Subclinical Left Ventricular Dysfunction During Chemotherapy
title_short	Subclinical Left Ventricular Dysfunction During Chemotherapy
title_full	Subclinical Left Ventricular Dysfunction During Chemotherapy
title_fullStr	Subclinical Left Ventricular Dysfunction During Chemotherapy
title_full_unstemmed	Subclinical Left Ventricular Dysfunction During Chemotherapy
title_sort	subclinical left ventricular dysfunction during chemotherapy
publisher	Radcliffe Medical Media
publishDate	2019
url	https://doaj.org/article/d54911864c4841cab1ed25766781d4e9
work_keys_str_mv	AT martinnicol subclinicalleftventriculardysfunctionduringchemotherapy AT mathildebaudet subclinicalleftventriculardysfunctionduringchemotherapy AT alaincohensolal subclinicalleftventriculardysfunctionduringchemotherapy
_version_	1718372821624684544

Subclinical Left Ventricular Dysfunction During Chemotherapy

Ejemplares similares